Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc due to misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints [1][2]. Group 1: Lawsuit Details - The lawsuit, Megan Dodge v. Mereo BioPharma Group plc, was initiated in the United States District Court for the Southern District of New York for investors who purchased American Depositary Shares (ADS) between June 5, 2023, and December 26, 2025 [1]. - Investors are encouraged to participate in the lawsuit before the April 6, 2026 deadline to potentially recover losses [5]. Group 2: Study Results - Mereo announced on December 29, 2025, that neither the ORBIT nor the COSMIC Phase 3 studies achieved statistical significance, failing to meet the primary endpoint of reducing annualized clinical fracture rates compared to placebo or bisphosphonates [3]. - Despite improvements in bone mineral density, the studies did not yield the expected results, leading to significant investor concerns [2][3]. Group 3: Market Reaction - Following the announcement of the study results, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, marking a decline of over 87.7% [4].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging that the company misled investors regarding the results of its Phase 3 studies for the drug setrusumab, which is intended for treating Osteogenesis Imperfecta [1][2]. Group 1: Allegations and Misleading Information - The lawsuit claims that Mereo BioPharma provided investors with overly optimistic statements about the expected outcomes of the Phase 3 ORBIT and COSMIC studies, asserting confidence in setrusumab's ability to reduce annualized fracture rates [2]. - It is alleged that while making these positive statements, Mereo concealed material adverse facts about the studies, which ultimately did not meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo or bisphosphonate control groups [2][3]. Group 2: Impact on Stock Price - Following the announcement on December 29, 2025, that neither the ORBIT nor COSMIC studies met their primary endpoints, Mereo's American Depository Shares (ADS) plummeted from $2.31 per share to $0.29 per share, marking a decline of over 87.7% [3]. Group 3: Class Action Participation - Shareholders of Mereo BioPharma may be eligible to participate in the class action lawsuit, with options to serve as lead plaintiff or remain an absent class member [4].

Company Overview - Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative medicines to address serious unmet medical needs, particularly in oncology [6] - The company aims to integrate traditional biology research with advanced engineering to expedite the development of better medicines [6] Initial Public Offering (IPO) Details - Eikon has priced its upsized initial public offering at $18.00 per share, offering a total of 21,177,600 shares, which is expected to generate approximately $381 million in gross proceeds [1] - The underwriters have a 30-day option to purchase an additional 3,176,640 shares at the same initial public offering price [1] - The IPO is set to begin trading on the Nasdaq Global Select Market under the ticker symbol "EIKN" on February 5, 2026, with the offering expected to close on or about February 6, 2026 [2] Regulatory and Compliance Information - A registration statement on Form S-1 related to the offering has been filed with the SEC and was declared effective on January 30, 2026 [3] - The offering is being conducted solely through a prospectus that is part of the effective registration statement [4]

Core Viewpoint - The Ultragenyx class action lawsuit alleges that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab, leading to significant stock price declines when the truth was revealed [4][5][6]. Company Overview - Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases [3]. Allegations of the Lawsuit - The lawsuit claims that Ultragenyx misrepresented the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta (OI) patients and downplayed the risks associated with the Phase III Orbit study [4]. - It is alleged that Ultragenyx's optimism regarding the Phase III Orbit study was unfounded, as the results were based on Phase II data without a placebo control group, which could have led to misleading conclusions about the drug's effectiveness [4]. Stock Price Impact - Following the announcement on July 9, 2025, that the Phase III Orbit study did not achieve statistical significance, Ultragenyx's stock price fell by over 25% [5]. - On December 29, 2025, after revealing that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, the stock price dropped by more than 42% [6]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Ultragenyx common stock during the Class Period to seek appointment as lead plaintiff in the class action lawsuit [7]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [7]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is recognized for recovering over $916 million for investors in 2025 and has a strong track record in securities class action recoveries, totaling $8.4 billion over the past five years [8].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, alleging that the company misled investors regarding the Phase III Orbit and Cosmic Studies for setrusumab [1][2]. Allegations - The lawsuit claims that during the class period, Ultragenyx provided investors with overly positive information about the expected results of the Phase III Orbit and Cosmic Studies, which tested setrusumab in patients with Osteogenesis Imperfecta (OI) [2]. - Defendants allegedly expressed confidence in setrusumab's ability to reduce the annualized fracture rate in OI patients and in the study designs to demonstrate this ability, while concealing material adverse facts about the drug's true potential and the risks associated with the study protocols [3]. Study Results and Impact - On December 29, 2025, Ultragenyx announced that the Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing the annualized clinical fracture rate compared to placebo or bisphosphonates [4]. - Following this announcement, Ultragenyx's stock price plummeted from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in just one day [4]. Next Steps for Shareholders - Shareholders interested in participating in the class action against Ultragenyx are encouraged to contact Robbins LLP, with the option to serve as lead plaintiff or remain an absent class member [5].

Market Overview - The S&P 500 fell 0.51% to 6,882.72, while the Nasdaq Composite slid 1.51% to 22,904.58 due to heavy tech selling. The Dow Jones Industrial Average rose 0.53% to 49,501.30 as investors shifted towards defensive and value stocks [1] Company Performance - Advanced Micro Devices (AMD) experienced a significant drop of 17.31% despite reporting solid earnings, closing at $200.19. The company's Q1 forecast did not meet high market expectations [2] - Software stocks, including Thomson Reuters, saw substantial declines, with Thomson Reuters down over 20% in the past five days. Conversely, biopharmaceutical company Amgen gained over 8% on positive Q4 results, contributing to the Dow's positive performance [3] Market Sentiment - The Nasdaq's decline reflects skepticism towards AI, highlighted by the steep sell-off of AMD. SanDisk also fell nearly 16%, erasing recent gains. The release of new AI tools by Anthropic is pressuring software and services companies, leading to a loss of around $300 billion in software and financial services stocks [4] - The tech upheaval is causing capital to rotate towards defensive and cyclical stocks, as evidenced by the Dow's gains. Disappointing jobs data from ADP, which reported only 22,000 private payroll additions in January against a forecast of 45,000, has added to investor uncertainty [5]

Core Viewpoint - Vanda Pharmaceuticals Inc. will release its financial results for the fourth quarter and full year 2025 on February 11, 2026, after market close [1]. Group 1: Financial Results Announcement - The financial results will be discussed during a conference call scheduled for 4:30 PM ET on February 11, 2026 [2]. - The conference call will be accessible via a domestic dial-in number (1-888-596-4144) and an international number (1-646-968-2525) with a passcode of 8728050 [2]. Group 2: Conference Call Details - The conference call will be broadcast live and archived on Vanda's website, encouraging investors to register and prepare in advance [3]. - A replay of the conference call will be available starting at 8:30 PM ET on February 11, 2026, until 11:59 PM ET on February 18, 2026, with specific call-in numbers for domestic (1-800-770-2030) and international (1-609-800-9909) callers [4]. Group 3: Company Overview - Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing innovative therapies to meet high unmet medical needs [5].

Core Viewpoint - A class action has been filed against Vistagen Therapeutics, Inc. for allegedly misleading investors regarding the viability of its Phase 3 trial study of fasedienol, leading to significant financial losses for shareholders [1][2]. Group 1: Class Action Details - The class action is on behalf of all investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025 [1][2]. - Allegations include that Vistagen provided misleading statements about the success of its Phase 3 PALISADE-3 trial for fasedienol while concealing adverse facts [2][3]. Group 2: Trial Results and Impact - On December 17, 2025, Vistagen announced that the PALISADE-3 trial did not show statistically significant improvement on its primary endpoint, leading to a dramatic stock price drop from $4.36 to $0.86, a decline of over 80% [3]. Group 3: Next Steps for Investors - Shareholders wishing to serve as lead plaintiffs must submit their papers by March 16, 2026, but participation is not required to be eligible for recovery [4].

As filed with the Securities and Exchange Commission on February 4, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Generate Biomedicines, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1630228 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 101 South Street, Suite 900 Somerville, MA 02143 (8 ...

Core Insights - NorthStrive Biosciences, a subsidiary of PMGC Holdings, has provided an update on the timeline for Phase III of its AI Development Program in collaboration with Yuva Biosciences, with results expected in Q2 2026 [1][3] Group 1: Company Updates - NorthStrive Biosciences initiated Phase III of its AI Development Program on December 17, 2025, which is anticipated to last approximately 6 to 9 weeks [1] - Yuva Biosciences has developed improved sixth-generation classifier models that enhance screening accuracy and sensitivity, which will be utilized in the Phase III study [2] - The extended timeline for Phase III results is expected to yield more robust and reliable outcomes to support further development efforts [3] Group 2: Company Background - Yuva Biosciences specializes in mitochondrial sciences and employs advanced AI to identify therapeutic candidates targeting aging-related pathways, with its proprietary platform MitoNova™ [4] - NorthStrive Biosciences focuses on developing aesthetic medicines, with its lead asset EL-22 aimed at addressing obesity while preserving muscle during weight loss treatments [5] - PMGC Holdings is a diversified holding company that manages a portfolio through strategic acquisitions and investments across various industries [6]